EUVIMED · CrossrefZeitschrift
Lung Cancer: Targets and Therapy
ISSN 1179-2728 · Informa UK Limited
Neueste Artikel
Expert Consensus Recommendations on NSCLC Management: Evidence-Based Strategies for Early Resectable and Locally Advanced Disease from Asia
Tiered Group of Disease Driven Oncogene Informs Survival Outcome of Taiwanese and Japanese Patients with Advanced NSCLC in the LC-SCRUM-Asia Study
Identification of JAML as an Immune-Associated Prognostic Marker in Non-Small Cell Lung Cancer
Healing of Post-Operative Tracheal Disruption in a Patient with Thymic Carcinoma on Adjuvant Immunotherapy
Can We Extend Beyond 2 Years of Adjuvant ALK TKI Established by ALINA and ELEVATE in Resected Early Stage ALK+ NSCLC a Disease with High Predilection for CNS Metastasis with Novel Clinical Trial Designs?
Unilateral Scleral Icterus as a Rare Presentation of Choroidal Metastasis in Transdifferentiated EGFR-Mutant Lung Cancer: A Case Report and Review of the Literature
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China
Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancer
Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC – Insights From Genomics, Proteomics, and Metabolomics
Adagrasib in KRYSTAL-12 has Broken the KRASG12C Enigma Code in Non-Small Cell Lung Carcinoma
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives
Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
Comprehensive review of fetal adenocarcinoma of the lung
Bevacizumab in the treatment of NSCLC: patient selection and perspectives
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
Oligometastatic non-small-cell lung cancer: current treatment strategies
Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer
Clinical staging of malignant pleural mesothelioma: current perspectives
Exhaled breath analysis for the early detection of lung cancer: recent developments and future prospects
Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
Prognostic value of soluble major histocompatibility complex class I polypeptide-related sequence A in non-small-cell lung cancer – significance and development
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma
New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
The role of maintenance pemetrexed in the treatment of non-small-cell lung cancer
Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer
EUVIMED